Clinical Commander

Back to dossier
cardio.hypertensive-emergency.eclampsia-hellp-overlap.v1PRODUCTION
cardio.hypertensive-emergency.eclampsia-hellp-overlap.v1

HELLP syndrome with severe HTN + eclampsia overlap (peripartum HTN crisis)

cardiologyacuteadultpregnancy
Hard-required inputs
0 / 12
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

HELLP overlap = pregnancy/postpartum + severe HTN + Hemolysis (LDH >600 + schistocytes) + Elevated Liver enzymes (AST/ALT >70) + Low Platelets (<100K) ± eclampsia. Mississippi class 1 (plt <50K) is highest mortality phenotype. Pregnancy-safe drug profile (labetalol/hydralazine/nifedipine + MgSO4) per ACOG 2020. URGENT DELIVERY is definitive treatment. Watch for subcapsular liver hematoma + DIC + AKI + abruption.

Inputs
5
Actions
0
Advance rule
Set
Advance when

HELLP overlap phenotype confirmed + Mississippi class assigned

Patient inputs (13)

Maternal age extremes (<20 or >35) increase HELLP severity + complication risk

Gestational age + HELLP class drives delivery urgency (Mississippi class 1 → expedited delivery regardless of GA; class 2/3 with stable mom → consider steroids 24-48h if <34 wk)

HELLP severity classification (Mississippi class 1: <50K; class 2: 50-100K; class 3: 100-150K). <50K + bleeding/surgery → platelet transfusion before delivery

AST/ALT >70 confirms HELLP transaminitis component; >2× ULN = severe feature; rising trend signals worsening disease

LDH >600 confirms hemolysis component of HELLP (Mississippi); >1400 indicates severe hemolysis with high adverse outcome risk

Schistocytes on smear confirm microangiopathic hemolytic anemia (MAHA) — distinguishes HELLP from acute fatty liver of pregnancy (AFLP) + TTP/HUS overlap

AKI (Cr ≥1.1 or doubling) — HELLP-AKI common; drives nephrology consult + transfusion timing + HD decision

Fibrinogen <300 + platelet drop → DIC overlap (occurs in ~20% severe HELLP); cryo + FFP for delivery preparation

Goal 4.8-8.4 mg/dL during MgSO4 infusion; reflex + RR + UOP check q1h

Continuous fetal monitoring — non-reassuring tracing in HELLP often heralds placental insufficiency / abruption

Goal SBP <160 within 30-60 min (ACOG 2020); preserve placental perfusion (avoid <130/80)

Goal DBP <110 within 30-60 min (ACOG 2020)

Imaging if RUQ pain + HELLP — rule out subcapsular hematoma (life-threatening; mortality ~60% if rupture); US first then CT/MRI per stability

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningsubcapsular_liver_hematoma_rupture
    Sudden RUQ pain + shock + hemoperitoneum in HELLP — subcapsular liver hematoma rupture (mortality ~60% if not emergently managed)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningeclampsia_seizure_breakthrough_in_hellp
    Seizure during MgSO4 in HELLP — reload + benzo + URGENT delivery (highest mortality phenotype)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningurgent_delivery_decision_in_hellp_class_1
    Mississippi HELLP class 1 (plt <50K + AST/ALT >70 + LDH >600) → urgent delivery regardless of GA + transfusion support
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningdic_overlap_with_hellp
    HELLP + DIC (fibrinogen <100, INR >1.5, D-dimer markedly elevated, active bleeding) — occurs in ~20% severe HELLP
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepostpartum_cardiomyopathy_unmasked_by_fluid_shifts
    New-onset CHF symptoms postpartum (orthopnea, edema, dyspnea) ± low EF on echo — peripartum cardiomyopathy unmasked by HELLP-related fluid shifts
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

HELLP overlap — pregnancy-safe BP control + MgSO4 + platelet/FFP/cryo transfusion + URGENT DELIVERY
axis: hellp_overlap_pregnancy_safe_bp_control_mgso4_transfusion
Selected axis "HELLP overlap — pregnancy-safe BP control + MgSO4 + platelet/FFP/cryo transfusion + URGENT DELIVERY" by default fallback (first axis)
  • labetalol
    first line
    mixed_alpha_beta_blocker
    20 mg IV → 40 mg → 80 mg q10 min (max 300 mg cumulative) • IV • bolus
    triggers: hellp_with_severe_htn, pregnancy_htn_emergency
    ACOG 2020 first-line; safe in pregnancy + HELLP; CHIPS PMID 25629739 supports tight BP control
    rxcui 6185
  • hydralazine
    first line
    arteriolar_vasodilator
    5-10 mg IV q15-20 min (max 30 mg cumulative) • IV • q15-20 min
    triggers: hellp_alt_to_labetalol, labetalol_contraindication
    ACOG 2020 alternative; safe in pregnancy + HELLP
    rxcui 5487
  • nifedipine
    first line
    DHP_CCB
    10-20 mg PO immediate-release, repeat in 30 min if no response (max 50 mg/h) • PO • q30 min × 2 then q4-6h
    triggers: hellp_PO_route_available, IV_access_pending
    ACOG 2020 first-line oral option; monitor for hypotension with concurrent MgSO4
    rxcui 7417
  • magnesium sulfate
    first line
    NMDA_antagonist_anticonvulsant
    4-6 g IV load over 20 min then 1-2 g/h infusion • IV • continuous
    triggers: hellp_with_severe_features, eclampsia_overlap
    MAGPIE PMID 12053139 + Lucas PMID 7494569 — primary anti-seizure prophylaxis + treatment per ACOG 2020; goal Mg 4.8-8.4 mg/dL; reflex + RR + UOP q1h
    rxcui 6585
  • lorazepam
    rescue
    benzodiazepine
    2-4 mg IV • IV • PRN seizure breakthrough on MgSO4
    triggers: eclampsia_seizure_breakthrough_on_mgso4_in_hellp
    Adjunct AED for refractory seizures on MgSO4; consider levetiracetam if recurrent
    rxcui 6470
  • dexamethasone
    add on
    corticosteroid
    10 mg IV q12h × 2-4 doses (debated benefit) • IV • q12h
    triggers: hellp_class_1_or_2_with_pregnancy_lt_34_weeks, fetal_lung_maturity_indication
    Antenatal corticosteroid for fetal lung maturity if <34 wk (Class I); maternal dexamethasone for HELLP plt recovery debated — Cochrane meta (Woudstra 2010) shows small plt rise but no maternal mortality benefit; Mississippi protocol uses; consider when delaying delivery 24-48h benefits fetus
    rxcui 3264
  • metoprolol
    add on
    beta_blocker_postpartum_only
    25 mg PO BID titrate (postpartum only — not first-line antepartum) • PO • BID
    triggers: postpartum_HTN_management_after_hellp
    Postpartum oral BB; AVOID atenolol antepartum (FGR association); metoprolol acceptable postpartum + during lactation (compatible)
    rxcui 6918
  • platelet transfusion (1 unit pheresis = 6-pack)
    rescue
    blood_product
    Goal plt >50K for vaginal delivery, >80K for C-section; transfuse if plt <20K (any bleeding) OR <50K + active bleeding/surgery • IV • pre-procedure or active bleed
    triggers: hellp_class_1_pre_delivery, plt_lt_20K_any_bleeding, plt_lt_50K_with_C_section_planned
    ACOG 2020; Sibai PMID 15467566 — platelet support drives delivery safety in Mississippi class 1
  • FFP + cryoprecipitate (DIC support)
    rescue
    blood_product
    FFP 10-15 mL/kg if INR >1.5 + bleeding; cryo 10 units if fibrinogen <100 • IV • as bleeding/INR/fibrinogen dictates
    triggers: hellp_with_dic_overlap, fibrinogen_lt_100, inr_gt_1.5_with_bleeding
    DIC overlap occurs in ~20% severe HELLP; replacement protocol per OB hemorrhage standards
  • AVOID ACE inhibitors / ARBs antepartum
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: pregnancy_diagnosis
    Fetotoxic — oligohydramnios, renal dysgenesis, lung hypoplasia, IUGR; FDA Pregnancy Category D; ACOG Class III antepartum. Postpartum: enalapril/captopril lactation-compatible if needed.
  • AVOID nitroprusside in pregnancy
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: pregnancy_diagnosis
    Cyanide crosses placenta → fetal toxicity; ACOG 2020 AVOID
  • AVOID atenolol in pregnancy
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: pregnancy_diagnosis
    FGR association in 1st-trimester exposure; use labetalol or metoprolol postpartum if BB needed
  • URGENT DELIVERY (definitive treatment)
    first line
    obstetric_intervention
    Per OB judgment — C-section vs induction based on HELLP class + cervical readiness + fetal status • OR_or_LD • as needed
    triggers: hellp_class_1_any_GA, eclampsia_overlap, subcapsular_hematoma, placental_abruption, non_reassuring_fetal_status
    ACOG 2020 — delivery is curative; Mississippi class 1 → urgent regardless of GA; class 2/3 with stable mom <34 wk → individualized 24-48h steroids then deliver

outpatient playbook — drug actions (1)

  1. 1. continue oral antihypertensive if needed
    rxcui 6918
    Labetalol or nifedipine maintenance; ACEi/ARB if non-lactating • PO • daily
    trigger: Persistent HTN
    ACOG 2020 + ACC/AHA 2025

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: BP ≥160/110 in pregnancy/postpartum + HELLP triad on labs (plt <100K, AST/ALT >70, LDH >600) — ACOG 2020; Mississippi/Tennessee HELLP triad: hemolysis (LDH >600 + schistocytes + ↑indirect bili) + transaminitis (AST/ALT >70) + thrombocytopenia (plt <100K) — Sibai PMID 15467566; New RUQ or epigastric pain in pregnancy/postpartum + HTN — concern for HELLP / hepatic capsular distension / subcapsular hematoma.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**HELLP syndrome with severe HTN + eclampsia overlap (peripartum HTN crisis)** (cardio.hypertensive-emergency.eclampsia-hellp-overlap.v1).
Scope: HELLP overlap = pregnancy/postpartum + severe HTN + Hemolysis (LDH >600 + schistocytes) + Elevated Liver enzymes (AST/ALT >70) + Low Platelets (<100K) ± eclampsia. Mississippi class 1 (plt <50K) is highest mortality phenotype. Pregnancy-safe drug profile (labetalol/hydralazine/nifedipine + MgSO4) per ACOG 2020. URGENT DELIVERY is definitive treatment. Watch for subcapsular liver hematoma + DIC + AKI + abruption.

No severity triggers fired against current inputs.

Plan

Regimen axis: **HELLP overlap — pregnancy-safe BP control + MgSO4 + platelet/FFP/cryo transfusion + URGENT DELIVERY**.
1. labetalol 20 mg IV → 40 mg → 80 mg q10 min (max 300 mg cumulative) IV bolus (mixed_alpha_beta_blocker, first line) — ACOG 2020 first-line; safe in pregnancy + HELLP; CHIPS PMID 25629739 supports tight BP control
2. hydralazine 5-10 mg IV q15-20 min (max 30 mg cumulative) IV q15-20 min (arteriolar_vasodilator, first line) — ACOG 2020 alternative; safe in pregnancy + HELLP
3. nifedipine 10-20 mg PO immediate-release, repeat in 30 min if no response (max 50 mg/h) PO q30 min × 2 then q4-6h (DHP_CCB, first line) — ACOG 2020 first-line oral option; monitor for hypotension with concurrent MgSO4
4. magnesium sulfate 4-6 g IV load over 20 min then 1-2 g/h infusion IV continuous (NMDA_antagonist_anticonvulsant, first line) — MAGPIE PMID 12053139 + Lucas PMID 7494569 — primary anti-seizure prophylaxis + treatment per ACOG 2020; goal Mg 4.8-8.4 mg/dL; reflex + RR + UOP q1h
5. lorazepam 2-4 mg IV IV PRN seizure breakthrough on MgSO4 (benzodiazepine, rescue) — Adjunct AED for refractory seizures on MgSO4; consider levetiracetam if recurrent
6. dexamethasone 10 mg IV q12h × 2-4 doses (debated benefit) IV q12h (corticosteroid, add on) — Antenatal corticosteroid for fetal lung maturity if <34 wk (Class I); maternal dexamethasone for HELLP plt recovery debated — Cochrane meta (Woudstra 2010) shows small plt rise but no maternal mortality benefit; Mississippi protocol uses; consider when delaying delivery 24-48h benefits fetus
7. metoprolol 25 mg PO BID titrate (postpartum only — not first-line antepartum) PO BID (beta_blocker_postpartum_only, add on) — Postpartum oral BB; AVOID atenolol antepartum (FGR association); metoprolol acceptable postpartum + during lactation (compatible)
8. platelet transfusion (1 unit pheresis = 6-pack) Goal plt >50K for vaginal delivery, >80K for C-section; transfuse if plt <20K (any bleeding) OR <50K + active bleeding/surgery IV pre-procedure or active bleed (blood_product, rescue) — ACOG 2020; Sibai PMID 15467566 — platelet support drives delivery safety in Mississippi class 1
9. FFP + cryoprecipitate (DIC support) FFP 10-15 mL/kg if INR >1.5 + bleeding; cryo 10 units if fibrinogen <100 IV as bleeding/INR/fibrinogen dictates (blood_product, rescue) — DIC overlap occurs in ~20% severe HELLP; replacement protocol per OB hemorrhage standards
10. AVOID ACE inhibitors / ARBs antepartum AVOID N/A N/A (do_not_use, contraindication substitute) — Fetotoxic — oligohydramnios, renal dysgenesis, lung hypoplasia, IUGR; FDA Pregnancy Category D; ACOG Class III antepartum. Postpartum: enalapril/captopril lactation-compatible if needed.
11. AVOID nitroprusside in pregnancy AVOID N/A N/A (do_not_use, contraindication substitute) — Cyanide crosses placenta → fetal toxicity; ACOG 2020 AVOID
12. AVOID atenolol in pregnancy AVOID N/A N/A (do_not_use, contraindication substitute) — FGR association in 1st-trimester exposure; use labetalol or metoprolol postpartum if BB needed
13. URGENT DELIVERY (definitive treatment) Per OB judgment — C-section vs induction based on HELLP class + cervical readiness + fetal status OR_or_LD as needed (obstetric_intervention, first line) — ACOG 2020 — delivery is curative; Mississippi class 1 → urgent regardless of GA; class 2/3 with stable mom <34 wk → individualized 24-48h steroids then deliver

Setting playbook (outpatient) — Long-term postpartum follow-up — chronic HTN ~40% develop within 1 yr; lifetime CV risk elevation discussion; subsequent pregnancy planning with prophylactic aspirin
14. continue oral antihypertensive if needed Labetalol or nifedipine maintenance; ACEi/ARB if non-lactating PO daily — Persistent HTN (ACOG 2020 + ACC/AHA 2025)

Non-pharmacologic actions:
- Lifetime CV risk discussion (HELLP independent CV risk factor — Bellamy BMJ 2007)
- Subsequent pregnancy: low-dose aspirin starting 12-28 wk per USPSTF 2021 (HELLP = high-risk)
- Annual BP + lipid + A1c

AVOID / contraindication checks:
- ACEi_ARB_avoid_antepartum_fetotoxic (ACOG 2020)
- Nitroprusside_avoid_pregnancy_fetal_cyanide (ACOG 2020)
- Atenolol_avoid_pregnancy_FGR (ACOG 2020)
- Avoid_BP_drop_below_130_80_preserves_placental_perfusion (ACOG 2020)
- Mgso4_check_reflexes_RR_UOP_q1h (ACOG 2020)
- Nifedipine_immediate_release_caution_with_mgso4_hypotension (ACOG 2020)
- NSAID_avoid_in_hellp_renal_and_plt_risk (ACOG 2020)
- Platelet_transfusion_target_50K_vaginal_80K_csection (Sibai PMID 15467566)

Monitoring

Regimen monitoring:
- q5-15min BP during acute phase (ACOG 2020)
- continuous fetal HR monitoring antepartum (ACOG 2020)
- q1h reflexes RR UOP during mgso4 infusion (ACOG 2020)
- q4-6h CBC LFTs LDH fibrinogen Cr until trending recovery (Sibai PMID 15467566)
- mg level q6h target 4.8-8.4 (ACOG 2020)
- daily liver imaging if hematoma noted (ACOG 2020)
- continuous postpartum monitoring x 24-48h for HELLP peak then recovery (Sibai)
- postpartum echo if PPCM concern BP shifts unmask (ACOG 2020)

Setting (outpatient) monitoring:
- Annual BP + lipid + A1c
- Quarterly visits if persistent HTN

Follow-up plan: Postpartum: HELLP labs typically peak 24-48h postpartum then recover by day 5-7; continue MgSO4 24h post-delivery; HTN often persists 1-2 wk postpartum (40% have chronic HTN at 1 yr); switch to PO labetalol/nifedipine; AVOID ACEi/ARB until lactation considerations addressed (enalapril/captopril lactation-compatible); 1-2 wk + 6-wk postpartum BP check; 3-mo cardiology + nephrology assessment; lifetime CV risk discussion (Bellamy BMJ 2007)
- Close-out criterion: postpartum oral regimen + 1-2 wk follow-up booked + lifetime CV risk educated

Monitoring phase: q5-15 min BP; continuous fetal monitoring antepartum; q1h reflex+RR+UOP during MgSO4; q4-6h CBC + LFTs + Cr + LDH + fibrinogen until trending toward recovery; daily liver imaging if hematoma noted; postpartum echo if PPCM concern (BP shifts may unmask)

Disposition

Current setting: outpatient — Long-term postpartum follow-up — chronic HTN ~40% develop within 1 yr; lifetime CV risk elevation discussion; subsequent pregnancy planning with prophylactic aspirin

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + lifetime CV risk panel

Escalation triggers (move to higher acuity):
- BP rebound → escalate per HTN ladder
- Subsequent pregnancy → preconception counseling + early aspirin

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Sudden RUQ pain + shock + hemoperitoneum in HELLP — subcapsular liver hematoma rupture (mortality ~60% if not emergently managed)
- [LIFE_THREATENING] Seizure during MgSO4 in HELLP — reload + benzo + URGENT delivery (highest mortality phenotype)
- [LIFE_THREATENING] Mississippi HELLP class 1 (plt <50K + AST/ALT >70 + LDH >600) → urgent delivery regardless of GA + transfusion support

Citations

- ACOG Practice Bulletin 222 (2020/2022) Severe Pre-eclampsia + HELLP + 2025 ACC/AHA HTN (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) + Sibai HELLP review (PMID 15467566) [PMID:38316810](https://pubmed.ncbi.nlm.nih.gov/38316810/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 12053139) [PMID:12053139](https://pubmed.ncbi.nlm.nih.gov/12053139/)
- Cited evidence (PMID 7494569) [PMID:7494569](https://pubmed.ncbi.nlm.nih.gov/7494569/)
- Cited evidence (PMID 15467566) [PMID:15467566](https://pubmed.ncbi.nlm.nih.gov/15467566/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ACOG Practice Bulletin 222 (2020/2022) Severe Pre-eclampsia + HELLP + 2025 ACC/AHA HTN (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) + Sibai HELLP review (PMID 15467566) — PMID:38316810
  • Cited evidence (PMID 38613493) — PMID:38613493
  • Cited evidence (PMID 12053139) — PMID:12053139
  • Cited evidence (PMID 7494569) — PMID:7494569
  • Cited evidence (PMID 15467566) — PMID:15467566